

Disclosures

Personal Commercial (6)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Research/Research Grants	Significant (>= \$5,000)	Valvular Heart Disease
Cardiovascular Research Foundation	Data Safety Monitoring Board	Significant (>= \$5,000)	Valvular Heart Disease
Edwards Lifesciences	Consultant Fees/Honoraria	Significant (>= \$5,000)	Valvular Heart Disease
Edwards Lifesciences	Research/Research Grants	Significant (>= \$5,000)	Valvular Heart Disease
Edwards Lifesciences	Research/Research Grants † Evaluation of the Identification and Management of Severe Aortic Stenosis within a Large Academic Health System	Significant (>= \$5,000)	Valvular Heart Disease
Medtronic	Research/Research Grants † HALT Biomarker Study	Significant (>= \$5,000)	Valvular Heart Disease

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (5)

Trial Name	Trial Sponsor	Trial Funding Source
REPAIR MR	Abbott Laboratories	
PROGRESS Trial	Edwards Lifesciences	
CLASP IITR	Edwards Lifesciences	
TRISCEND II Trial	Edwards Lifesciences	
CLASP IIF	Edwards Lifesciences	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2020	STEMI & aplastic anemia	Defendant † Ratcliffe Harten Galamaga LLP	Patient with aplastic anemia & STEMI and treated with DAPT/heparin prior to PCI c/b ICH.	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 11/19/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 11/19/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 11/19/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.